The Phacilitate Vaccine Forum has set the standard for senior-level industry events for the past 13 years.

And in 2014, we promise to deliver more key decision-makers from the global industry and wider community (including leading public and private sector investors, NGOs and regulators) than ever before.

Brand new for 2014, we introduce a dedicated focus on immunotherapy – currently THE most significant emerging technology area in the eyes of big pharma, biotech and academia alike. These conference streams will run in parallel to our established prophylactic vaccine content over the course of the three days, giving our delegates the option to attend sessions on either or both areas, according to their personal preference.

As in previous years, the event will be collocated with the well-established Cell & Gene Therapy Forum (10th Annual). We will deliver 500-600 attendees in total at our Washington 2014 meeting, including a speaker panel exceeding 150 members; an unprecedented guarantee of leading corporate, R&D, manufacturing and regulatory decision-makers for you to learn from – and meet – in a business-focused, yet informal environment ideal for top-level networking and knowledge exchange – a Phacilitate hallmark.

PLUS delegates will receive access to an online pre-event Partnering Service, allowing them to contact individuals and organise meetings before they arrive onsite.

Visit us again soon for updates on the agenda and confirmed speaker panel. In the meantime, register your interest in attending the event as a delegate here or receive information on already-limited remaining sponsorship and exhibition opportunities by contacting Michael Adeniya, Business Development Director (Michael@phacilitate.co.uk; +44 (0)20 7384 7951).